Clinical trials
Completed Observational trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
775 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 6 |
| 2004 | 10 |
| 2005 | 11 |
| 2006 | 7 |
| 2007 | 22 |
| 2008 | 26 |
| 2009 | 30 |
| 2010 | 37 |
| 2011 | 36 |
| 2012 | 45 |
| 2013 | 47 |
| 2014 | 50 |
| 2015 | 54 |
| 2016 | 53 |
| 2017 | 49 |
| 2018 | 46 |
| 2019 | 46 |
| 2020 | 43 |
| 2021 | 42 |
| 2022 | 41 |
| 2023 | 33 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 775 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 69 |
| Bayer | 62 |
| Takeda | 51 |
| Pfizer | 44 |
| Boehringer Ingelheim | 39 |
| Novo Nordisk A/S | 36 |
| Bristol-Myers Squibb | 30 |
| Eisai Co., Ltd. | 26 |
| Astellas Pharma Inc | 25 |
| AbbVie | 21 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 45 |
| Carcinoma, Non-Small-Cell Lung | 23 |
| Coronary Artery Disease | 23 |
| Diabetes Mellitus | 21 |
| Arthritis, Rheumatoid | 17 |
| Atrial Fibrillation | 17 |
| Pulmonary Disease, Chronic Obstructive | 17 |
| Asthma | 16 |
| Heart Failure | 15 |
| Hypertension | 13 |
Trials
Showing 1 to 25 of 775. Each trial links to its page on Pharma Observatory.
675 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.